150 mg, prolonged-release hard capsules
Venlafaxine
Alventa contains the active substance venlafaxine.
Alventa is an antidepressant that belongs to a group of medicines called serotonin and norepinephrine reuptake inhibitors (SNRIs). Medicines in this group are used to treat depression and other conditions such as anxiety disorders. It is believed that in people with depression and/or anxiety, there is a lower concentration of serotonin and norepinephrine in the brain. The mechanism of action of antidepressants is not fully understood, but they may help by increasing the concentration of serotonin and norepinephrine in the brain.
Alventa is used to treat depression in adults. Alventa is also indicated for the treatment of the following anxiety disorders in adults: generalized anxiety disorder, social phobia (fear or avoidance of social situations), and panic disorder (panic attacks). For the patient to feel better, it is essential that the treatment of depression and anxiety disorders is carried out correctly. If the treatment is not started, the patient's condition may not improve, worsen, and become more difficult to treat.
point "Alventa and other medicines" and the information in this section about serotonin syndrome).
Before starting to take Alventa, the patient should discuss with their doctor or pharmacist:
Alventa may cause feelings of restlessness or inability to sit or stand still during the first few weeks of treatment. If such symptoms occur, the patient should inform their doctor.
Suicidal thoughts and worsening of depression or anxiety disorders
People with depression or anxiety disorders may sometimes have thoughts of self-harm or suicide. Such symptoms or behavior may worsen at the start of treatment with antidepressants, as these medicines usually start to work after about 2 weeks, sometimes later. Such thoughts may also occur after reducing the dose or during withdrawal from Alventa.
These thoughts of suicide or self-harm are more likely to occur in:
If the patient experiences thoughts of self-harm or suicide, they should immediately contact their doctor or go to the nearest hospital emergency department.
It may be helpful to inform relatives or friends about the depression or anxiety disorder and ask them to read this leaflet. The patient may ask them to monitor their condition and inform them if they notice any worsening of depression or anxiety or any worrying changes in the patient's behavior.
Sexual dysfunction
Medicines like Alventa (so-called SSRIs or SNRIs) may cause sexual dysfunction (see section 4). In some cases, these symptoms persisted after stopping treatment.
Dry mouth
Dry mouth is reported by 10% of patients treated with venlafaxine. This may increase the risk of tooth decay. Therefore, it is essential to take good care of oral hygiene.
Diabetes
Alventa may affect blood sugar levels, and it may be necessary to adjust the dose of antidiabetic medicines.
Children and adolescents
Alventa should not be used in children and adolescents under 18 years of age.
It should also be noted that patients under 18 years of age who take medicines in this group are at increased risk of side effects, such as suicidal attempts, suicidal thoughts, and hostility (especially aggression, rebellious behavior, and manifestations of anger).
However, the doctor may prescribe this medicine to patients under 18 years of age if they consider it beneficial. If the doctor has prescribed this medicine to a patient under 18 years of age, in case of doubts, the patient should consult their doctor to discuss it. The patient should inform their doctor if any of the above symptoms or any other symptoms worsen in patients under 18 years of age taking Alventa. There is also no evidence of long-term safety regarding the effect on growth, maturation, and development of cognitive and behavioral functions in this age group.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
The doctor will decide whether to use Alventa with other medicines.
The patient should not start or stop taking other medicines, including over-the-counter medicines, herbal or natural remedies, without first consulting their doctor or pharmacist.
Subjective and objective symptoms of serotonin syndrome may include a combination of the following symptoms: restlessness, hallucinations, loss of coordination, rapid heartbeat, elevated body temperature, rapid changes in blood pressure, overreactivity, diarrhea, coma, nausea, vomiting.
The most severe form of serotonin syndrome may resemble neuroleptic malignant syndrome. Its symptoms include fever, rapid heartbeat, sweating, muscle stiffness, disorientation, increased muscle enzyme levels (detected in a blood test).
If serotonin syndrome is suspected, the patient should immediately tell their doctor or go to the nearest hospital emergency department.
If the patient is taking medicines that may affect heart rhythm, they should inform their doctor. Examples of such medicines:
The following medicines may also interact with Alventa, and the patient should use them with caution. It is especially important to inform the doctor if the patient is taking medicines containing:
Alventa should be taken with food (see section 3 "How to take Alventa").
The patient should avoid drinking alcohol while taking Alventa.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult their doctor or pharmacist before taking this medicine.
Alventa should only be used after discussing the potential benefits and potential risks to the unborn child with the doctor.
Taking Alventa at the end of pregnancy may increase the risk of severe postpartum hemorrhage, especially if the patient has a history of bleeding disorders. If the patient is taking Alventa, they should inform their doctor or midwife so that they can provide appropriate advice.
The patient should inform their doctor and/or midwife about taking Alventa. Taking similar medicines during pregnancy (such as SSRIs) may increase the risk of severe complications in the newborn, called persistent pulmonary hypertension of the newborn (PPHN), which is characterized by rapid breathing and cyanosis. These symptoms usually occur within the first day of life. If such symptoms occur in the newborn, the patient should immediately contact their doctor and/or midwife.
If the patient is taking this medicine during pregnancy, their child may experience difficulties with breathing or feeding after birth, in addition to other symptoms. If the patient is concerned about such symptoms in their newborn, they should contact their doctor and/or midwife, who will be able to provide appropriate advice.
Alventa passes into breast milk. There is a risk of an effect on the baby.
Therefore, the patient should discuss this with their doctor, and the doctor will decide whether to stop breastfeeding or stop treatment with this medicine.
The patient should not drive or operate machinery until they know how this medicine affects them.
If the patient has been informed by their doctor that they have an intolerance to some sugars, they should consult their doctor before taking this medicine.
This medicine should always be taken exactly as prescribed by the doctor or pharmacist. In case of doubts, the patient should consult their doctor or pharmacist.
Alventa is available in doses of 37.5 mg, 75 mg, and 150 mg.
Usually, the recommended initial dose for the treatment of depression, generalized anxiety disorder, social phobia is 75 mg per day. This dose may be gradually increased by the doctor if necessary, up to a maximum dose of 375 mg per day in the case of depression. In the case of panic disorder, treatment should be started with a lower dose (37.5 mg) and then gradually increased. The maximum dose for the treatment of generalized anxiety disorder, social phobia, and panic disorder is 225 mg per day.
Alventa should be taken once a day, at approximately the same time, regardless of whether it is taken in the morning or evening. The capsules should be swallowed whole with a drink of water.
They should not be divided, crushed, chewed, or dissolved.
Alventa should be taken with food.
The patient should inform their doctor about liver or kidney problems, as it may be necessary to adjust the dose.
The patient should not stop taking this medicine without consulting their doctor (see the section "Stopping Alventa").
In case of taking a higher dose of this medicine than recommended, the patient should immediately contact their doctor.
Symptoms of possible overdose may include rapid heartbeat, changes in consciousness (from drowsiness to coma), changes in vision, seizures or convulsions, and vomiting.
In case of missing a dose, the patient should take it as soon as possible. However, if it is almost time for the next dose, the patient should skip the missed dose and take only one dose at the usual time. The patient should not take a double dose of the medicine to make up for the missed dose. The patient should not take a higher dose in one day than the daily dose of Alventa prescribed by their doctor.
The patient should not stop treatment or reduce the dose without consulting their doctor, even if they feel better. If the doctor decides that it is possible to stop Alventa, they will inform the patient how to gradually reduce the dose before completely stopping treatment. In patients stopping Alventa, especially if treatment is stopped abruptly or the dose is reduced too quickly, side effects may occur, such as suicidal thoughts, aggression, feeling tired, dizziness, feeling empty-headed, headache, insomnia, nightmares, dry mouth, loss of appetite, nausea, diarrhea, nervousness, agitation, disorientation, ringing in the ears, tingling or numbness, weakness, sweating, seizures, or flu-like symptoms, vision problems, and increased blood pressure (which may cause headaches, dizziness, ringing in the ears, sweating, etc.).
The doctor will advise the patient on how to gradually stop Alventa. This may take several weeks or months. In some patients, it may be necessary to stop the medicine very gradually over several months or longer. If any of the above symptoms or other symptoms that are troublesome to the patient occur, they should consult their doctor.
In case of any further doubts about taking this medicine, the patient should consult their doctor or pharmacist.
Like all medicines, Alventa can cause side effects, although not everybody gets them.
In case of experiencing any of the following side effects, the patient should stop taking Alventa and contact their doctor immediately or go to the nearest hospital emergency department.
If the patient experiences any of the following side effects, they should contact their doctor.
(The frequency of these side effects has been reported in the section "Other side effects" below):
Alventa may sometimes cause side effects that the patient may not be aware of, such as increased blood pressure or abnormal heart rhythm; slight changes in sodium, cholesterol, or liver enzyme levels in the blood. In rare cases, Alventa may affect platelet function, leading to an increased risk of bruising or bleeding. Therefore, the doctor may recommend a blood test from time to time, especially during long-term treatment with Alventa.
If the patient experiences any side effects, including any side effects not listed in the leaflet, they should tell their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309,
website: https://smz.ezdrowie.gov.pl
Reporting side effects helps to gather more information on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
The patient should not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
There are no special precautions for storage.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Orange-brown capsules filled with white to almost white pellets.
Packaging:
10, 14, 20, 28, 30, 50, 60, 98, or 100 prolonged-release hard capsules in blisters, in a cardboard box.
For more detailed information, the patient should contact the marketing authorization holder or parallel importer.
KRKA, d.d., Novo mesto
Šmarješka cesta 6
8501 Novo mesto
Slovenia
KRKA, d.d., Novo mesto
Šmarješka cesta 6
8501 Novo mesto
Slovenia
Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Authorization number in Romania, the country of export:
4317/2012/01
4317/2012/02
4317/2012/03
4317/2012/04
4317/2012/05
4317/2012/06
4317/2012/07
4317/2012/08
[Information about the trademark]
Czech Republic | Olwexya |
Denmark, Finland, Iceland, Norway, Sweden | Venlafaxin Krka |
Estonia, Lithuania, Latvia, Slovakia | Alventa |
Spain | Venlafaxina Retard Krka |
Netherlands | Venlafaxine retard Krka |
Portugal | Venlafaxina Krka |
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.